[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bagcilar Training and Research Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100652305","predictive-value-of-inflammatory-biomarkers-for-mirabegron-response-in-women-with-overactive-bladder-100652305",false,"NCT07773532","Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder","Predictive Capacity of Baseline Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index for Mirabegron Treatment Response in Women With Overactive Bladder: A Prospective Cohort Study","Inclusion Criteria:\n\n* Female patients aged 18 years or older\n* Overactive bladder symptoms for at least 3 months\n* Mirabegron 50 mg planned by physician decision within routine care\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Any previous OAB-specific treatment other than behavioral therapy (oral antimuscarinic or beta-3 agonist, intravesical botulinum toxin, sacral neuromodulation, or posterior tibial nerve stimulation)\n* Acute infection within the last 4 weeks, including culture-confirmed urinary tract infection\n* Chronic inflammatory disease (rheumatologic or autoimmune disease, or inflammatory bowel disease)\n* Active malignancy or cancer treatment within the last 5 years\n* Use of systemic glucocorticoids within the last 4 weeks, or chronic NSAID or immunosuppressive use\n* Conditions affecting lower urinary tract function other than OAB (neurogenic bladder, urinary tract stones, history of pelvic radiotherapy or bladder surgery, pelvic organ prolapse stage 3 or higher, or stress-predominant mixed urinary incontinence)\n* Known diagnosis of hematologic disease, anemia (Hb\\\u003C9), or platelet disorder (PLT\\\u003C100.000 or \\>600.000)\n* Significant renal or hepatic impairment (eGFR below 30 mL\u002Fmin\u002F1.73 m2, or Child-Pugh class B or C)\n* Uncontrolled hypertension (180\u002F110 mmHg or higher) or any other contraindication to mirabegron\n* Pregnancy or lactation\n* Major surgery or trauma within the last 3 months\n* Cognitive or functional inability to complete the voiding diary","FEMALE","18 Years",{"count":19,"type":20},115,"ESTIMATED","OBSERVATIONAL","Overactive bladder (OAB) is associated with systemic chronic inflammation. Indices derived from complete blood count (such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)) have shown associations with OAB presence. However, whether baseline inflammatory status predicts response to beta-3 adrenergic agonist therapy remains untested. This prospective observational cohort study evaluates the predictive ability of baseline NLR, PLR, and SII for 3-month treatment response to mirabegron 50 mg in women with OAB.",[24],"Overactive Bladder (OAB)",[26,27,28,29,30,31,32,33,34,35,36],"Overactive Bladder","Adrenergic beta 3 Receptor Agonists","Inflammation","Biomarkers","Blood Cell Counts","Neutrophil-to-Lymphocyte Ratio","Platelet-to-Lymphocyte Ratio","Systemic Immune-Inflammation Index","NLR","PLR","SII","NOT_YET_RECRUITING","2026-08-18",{"date":40,"type":41},"2026-08-19","ACTUAL",{"date":43,"type":20},"2026-10-01",{"date":45,"type":20},"2027-11-01",{"name":47,"class":48},"Bagcilar Training and Research Hospital","OTHER_GOV",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100607251","methotrexate-treatment-in-cases-of-ectopic-pregnancy-with-relative-contraindications-100607251","NCT07186127","Methotrexate Treatment in Cases of Ectopic Pregnancy With Relative Contraindications","A Retrospective Evaluation of the Effectiveness of Methotrexate Treatment in Cases of Ectopic Pregnancy With Relative Contraindications","Inclusion Criteria:\n\n* Diagnosed with ectopic pregnancy\n* Received methotrexate (MTX) treatment\n* Underwent surgical treatment due to lack of response to MTX therapy\n* Compliant with treatment follow-up\n\nExclusion Criteria:\n\n* Participants with contraindications to methotrexate (MTX) treatment\n* Participants non-compliant with follow-up","48 Years",{"count":59,"type":20},230,"Study Description (For Patients, Families, and Healthcare Providers)\n\nPurpose:\n\nThe aim of this study is to evaluate the effectiveness and safety of methotrexate treatment in women with ectopic pregnancy who belong to a group for whom this treatment is relatively contraindicated.\n\nBackground:\n\nMethotrexate is a medication commonly used in the treatment of ectopic pregnancy (a pregnancy that occurs outside the uterus, usually in the fallopian tube). However, in certain conditions - such as kidney or liver dysfunction - methotrexate use may carry increased risks. These situations are known as relative contraindications. This study will retrospectively examine treatment outcomes in this specific patient population.\n\nMethod:\n\nThe study will analyze medical records of patients who were previously treated with methotrexate for ectopic pregnancy. No new interventions will be performed. The analysis will be based solely on existing clinical data.\n\nWhy Is This Important? The findings of this study may help us better understand the safety limits of methotrexate therapy and guide healthcare providers in managing similar cases in the future.",[62],"Ectopic Pregnancy",[62,64,65,66],"Relative Contraindication","Methotrexate","Laparoscopic surgery","RECRUITING","2025-09-15",{"date":70,"type":41},"2025-09-22",{"date":72,"type":41},"2025-05-01",{"date":74,"type":20},"2026-05-01",{"name":47,"class":48},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":49},"100554326","effect-of-spinal-needle-type-on-optic-nerve-sheath-diameter-100554326","NCT06497634","Effect of Spinal Needle Type on Optic Nerve Sheath Diameter","Effect of Needle Types and Diameters Using in Spinal Anesthesia on Optic Nerve Sheath Diameter; Prospective Randomized Study","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) I-II Risk Classification\n* Elective orthopedic lower extremity surgery\n* Using a tourniquet\n* Spinal anesthesia\n\nExclusion Criteria:\n\n* Bilateral tourniquet usage\n* History of orbital trauma\n* Optic nerve pathology\n* Glaucoma\n* Asthma\n* Coronary obstructive or pulmonary disease\n* Previous corneal or intraocular surgery\n* Increased intracranial pressure\n* Coagulopathy\n* Local site infection\n* Refusing to participate in the study","ALL","40 Years",{"count":86,"type":20},165,"INTERVENTIONAL",[89],"NA","The optic nerve sheath is a continuation of the dura mater, extending along the subarachnoid space surrounding the optic nerve. Consequently, changes in intracranial pressure cause an augmentation or contraction in the diameter of the optic nerve sheath, which is coreleted with intracranial pressure. Participants undergoing lower extremity operations (ankle, distal tibia and fibula surgeries) using a tourniquet under spinal anesthesia will be investigated. Spinal anesthesia will be performed with a 25 G Whitacre, 25 G Quincke, or 27 G Quincke needle, depending on the study group. Optic nerve sheath diameter (ONSD) measurements will be performed before spinal anesthesia; and 5 minutes, 15 minutes,,24 hours after spinal block, respectively.The 4th measurement will be performed after tourniquet is opened. Measurements will be done with 15 MHz linear ultrasound (US) probe in B mode, 3 mm behind the posterior globe in the transverse plane from both eyes, on upper eyelid. Values will be recorded numerically. The impact of spinal anesthesia administered using various needle designs (Quincke and Whitacre) and sizes (25G-27G) on intracranial pressure will be investigated.",[92,93,94,95,96],"Spinal Anesthesia","Intracranial Pressure Change","Optic Nerve Sheath Diameter","Orthopedic Surgery","Cerebrospinal Fluid Leak","2024-07-29",{"date":99,"type":41},"2024-07-30",{"date":101,"type":20},"2024-08-15",{"date":103,"type":20},"2024-12-30",{"name":47,"class":48},""]